Low-grade gliomas: clinical and pathobiological aspects.
The optimal management of patients with low-grade gliomas remains a challenge for the treating physician. The natural history of the disease shows a large variety, and there is a substantial controversy about many of everyday treatment recommendations. However, new developments in clinical and basic research in neuro-oncology have occurred during the last years. In this review some of these new insights into clinical and biological aspects of low-grade gliomas are discussed, with focus on the translation of new knowledge from basic research into clinical practice. For example, molecular genetic profiling of tumour material has started to guide treatment recommendations and clinical management of some patients with oligodendrogliomas. Experimental studies of the different molecular pathways in tumour cells and in their normal counterparts involved in cell-cycle check-point control have elucidated some of the underlying mechanisms of resistance of gliomas to radiotherapy and chemotherapy. Finally, improved classification of the different subtypes of low-grade gliomas may be achieved in the near future by characterization of the genetic heterogeneity within the tumour and by identification of a putative stem cell as the origin of the tumour cells.
Smits
A
A
Department of Neuroscience, Neurology, University Hospital, Uppsala, Sweden. Anja.Smits@neurologi.uu.se
D000818:Animals; D001254:Astrocytoma / Q000145:classification / Q000473:pathology / Q000628:therapy; D001932:Brain Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D018450:Disease Progression; D005910:Glioma / Q000145:classification / Q000473:pathology* / Q000628:therapy; D006801:Humans; D009837:Oligodendroglioma / Q000145:classification / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D016896:Treatment Outcome